Use this url to cite publication: https://hdl.handle.net/20.500.12512/117846
Options
Epitranscriptomic m6A modifications in glioma associated long-noncoding RNAs / Rugile Dragunaite, Giedrius Steponaitis, Rytis Stakaitis, Daina Skiriute
Type of publication
Tezės kitame recenzuojamame leidinyje / Theses in other peer-reviewed publication (T1e)
Title
Epitranscriptomic m6A modifications in glioma associated long-noncoding RNAs / Rugile Dragunaite, Giedrius Steponaitis, Rytis Stakaitis, Daina Skiriute
Publisher (trusted)
Lithuanian University of Health Sciences
Date Issued
2023-04-19
Extent
p. 31-32.
Is part of
Health for All: 2023 - International Conference Health for All “Rare diseases” : abstract book : Kaunas, Lithuania, 19-20th April, 2023 / [organised: Council of LSMU Doctoral Students]. Kaunas : Lithuanian University of Health Sciences, 2023.
Version
Originalus / Original
Description
Basic science
Bibliogr.: p. 32
Field of Science
Abstract
Introduction Glioblastoma (GBM) the most commonly occurring tumors of the central nervous system and a median life expectancy of 12.6 months, accounts for more than half of adult gliomas [1]. Long non-coding RNAs are involved in glioma initiation, progression, and infiltration/invasion processes by regulating the cellular proliferation, apoptosis, differentiation and ect. Lnc RNAs control the evolution of gliomas at the molecular level through epigenetic control, transcriptional and post-transcriptional modification [1,2]. Aim The current study's objective was to assess gene m6A modification in glioma pathology. Methods For total RNA extraction and poly-A RNA enrichment 24 snap-frozen human glioma tissues were used. RNA sequencing of 1µg of poly-A RNA was performed applying direct RNA sequencing from Oxford Nanopore Technologies (R9.4.1 flow cells). The \"m6Anet\" and \"Epinano\" pipelines were used to measure the ratio of modified m6As within RRACH motifs in the samples. Results Using DEseq, 49 genes were selected as differentially expressed between low and high malignancy glioma tumors (p<0.05), and out of this 10 highly m6A modified genes were screened out. Global adenine methylation level counted longitudinally of selected genes showed significantly higher methylation level in lower malignancy grade tumors. At the individual gene level m6A modification analysis of LINC00844 and SNHG6 genes revealed significantly lower m6A in GBM as compared to LGG (p<0.05). Patients with m6A-modified LINC00844, OTUD6B-AS1, and OIP5-AS1 genes had better survival prognoses(Log-rank test, p<0.05). Conclusions In conclusion, this study identified differences in lncRNA gene m6A modification level between LGG and GBM. At the gene level, m6A mark in genes LINC00844, OTUD6B-AS1, and OIP5-AS1 were linked to better patient survival, demonstrating the role of specific genes in glioma genesis.
Type of document
type::text::conference output::conference proceedings::conference paper
Other Identifier(s)
(LSMU ALMA)991701585707106
Coverage Spatial
Lietuva / Lithuania (LT)
Language
Anglų / English (en)
Bibliographic Details
2